GSK Enters Agreement to Acquire RAPT Therapeutics
January 21, 2026
January 21, 2026
LONDON, England, Jan. 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 20, 2026:
* * *
GSK enters agreement to acquire RAPT Therapeutics
* Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens
* Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing c . . .
* * *
GSK enters agreement to acquire RAPT Therapeutics
* Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens
* Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing c . . .